IgA-nefropátia: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BCMA 7
• CD19 8
• SGLT2 1
• CD20 0
• CD38 0
• IL-6 0
• JAK 0
• NLRP3 0
• TLR4 0
• mTOR 0
• STING 0
• IL-17 0
• AKT 0
• AMPK 0
• EGFR 0
• FAK 0
• GPX4 0
• HER2 0
• IL-1 0
• MET 0
• MYC 0
• NRF2 0
• PD-1 0
• PI3K 0
• STAT3 0
• TP53 0

369 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDDK · R01

  Determination of structural features critical for nephritogenic properties of IgA1-containing immune complexes in IgA nephropathy

  University of Alabama at Birmingham· Birmingham, Egyesült Államok· 743 278 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NIDDK · R01

  Dapagliflozin in Active Lupus Nephritis: A Pilot and Feasibility Randomized Trial

  Brigham and Women's Hospital· Boston, Egyesült Államok· 364 560 USD awarded in fiscal year 2026· until 2028. dec.

• NIH NIDDK · F32

  The Impact of APOL1 Copy Number Variation on Kidney Disease Susceptibility in African Americans

  Beth Israel Deaconess Medical Center· Boston, Egyesült Államok· 79 348 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIDDK · R01

  Interrogating The Biology Of Human Lupus Nephritis Using Single Cell Resolution Spatial Transcriptomics

  Seattle Children's Hospital· Seattle, Egyesült Államok· 801 241 USD awarded in fiscal year 2026· until 2028. jan.

• NIH NIAID · R01

  Contributions of autophagy-related genes in lupus

  Oklahoma Medical Research Foundation· Oklahoma City, Egyesült Államok· 751 755 USD awarded in fiscal year 2026· until 2027. júl.

• European Commission (Horizon Europe) · HORIZON-ERC

  Role of CD1c-reactive T cells and lipid antigens in post-streptococcal disease (CReativeLipid)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 1 491 316 EUR· until 2030. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Antigen-specific treatments to target autoimmune kidney diseases (AUTO-TARGET)

  Universitaetsklinikum Hamburg-Eppendorf· Hamburg, Németország· EU contribution 1 499 663 EUR· until 2030. márc.

• European Commission (Horizon Europe) · HORIZON-RIA

  Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology (geneTIGA)

  Charite - Universitaetsmedizin Berlin· Berlin, Németország· EU contribution 6 393 734 EUR· until 2026. dec.· 8 countries

8 of 22 running projects, newest first. Listed amounts together: 11,1 M USD + 9,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients

  NCT07022574· University of California, Los Angeles· Frissítve: 2026. júl. 27.

  “Unable to recruit”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

  NCT03608033· Omeros Corporation· Frissítve: 2025. dec. 9.

  “IA did not meet the prespecified primary endpoint.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

  NCT06926985· Jieyang People's Hospital· Frissítve: 2025. júl. 4.

  “Due to limitation of production capacity”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

  NCT05847920· Guangdong Hengrui Pharmaceutical Co., Ltd· Frissítve: 2025. márc. 5.

  “Based on the adjustment of the R \& D strategy, the sponsor decides to terminate the research.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

  NCT04905212· RemeGen Co., Ltd.· Frissítve: 2023. dec. 6.

  “Decision that continuing with the study would not generate useful data”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

  NCT07498335· Novartis Pharmaceuticals· Forrás

• A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Takeda· Forrás

• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Novartis Pharmaceuticals· Forrás

• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

  NCT05517980· Kira Pharmacenticals (US), LLC.· Forrás

• A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials

  2024-519638-22-00· Novartis Pharma AG· Forrás

• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Hoffmann-La Roche· Forrás

• Phase 2b Open-Label Repeat Kidney Biopsy Study

  NCT06740526· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás

• A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT07889362· Biogen· Forrás

• A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

  NCT07146906· Novartis Pharmaceuticals· Forrás

• Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)

  NCT07770815· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 14
• Gene Expression Profiling 14
• Proteomics 8
• Metabolomics 5
• Flow Cytometry 2
• Immunohistochemistry 4
• Magnetic Resonance Imaging 1
• Machine Learning 9
• Deep Learning 3
• Cohort Studies 14
• Genome-Wide Association Study 20

• Targeted-Release Budesonide in Chinese Patients with IgA Nephropathy: A Real-World Retrospective Cohort Study.

  Drug Des Devel Ther, 2026. okt.

• Long-Term Autoimmune Risk Following Pediatric Acute Pyelonephritis: A Nationwide Cohort Study.

  Pathogens, 2026. okt.

• Comparative Analysis of Clinical and Pathological Traits in IgA Nephropathy Patients with Nephrotic Syndrome or Nephrotic Range Proteinuria.

  Kidney Blood Press Res, 2026. szept.

• A First-in-Japanese Phase 1, Double-Blind, Placebo-Controlled, Parallel-Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants.

  Clin Pharmacol Drug Dev, 2026. szept.

• Impact of recurrent IgA nephropathy on long-term kidney transplant outcomes: a cohort comparison with autosomal dominant polycystic kidney disease.

  BMC Nephrol, 2026. aug.

• IgA nephropathy occurrence, treatment, and prognosis in the last two decades in Denmark.

  Nephrol Dial Transplant, 2026. júl.

• Incidence and risk factors for recurrent IgA nephropathy after kidney transplantation: A multicenter cohort study from Denmark.

  PLoS One, 2026. júl.

• Physician Variability in Time to Kidney Biopsy and Glucocorticoid Prescription in IgA Nephropathy: A Population-Based Cohort Study.

  Kidney360, 2026. máj.

• Landscape of kidney biopsy diagnoses in a Romanian pediatric cohort.

  BMC Nephrol, 2026. ápr.

• A nine-gene diagnostic model for IgA nephropathy based on multi-cohort machine learning: integrating gene expression and immunohistochemical validation.

  Ren Fail, 2026. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.